[{"id":"633b2bd1-281a-46a9-951a-65d15ed55de4","acronym":"NIR-II","url":"https://clinicaltrials.gov/study/NCT06713161","created_at":"2025-02-26T10:41:33.908Z","updated_at":"2025-02-26T10:41:33.908Z","phase":"","brief_title":"Tumor-Targeted-NIR-II Fluorescent Molecular Probes for the Identification of Breast Cancer Tissue and SLN Metastatic Status","source_id_and_acronym":"NCT06713161 - NIR-II","lead_sponsor":"Yunnan Cancer Hospital","biomarkers":" CXCR4","pipe":"","alterations":" ","tags":["CXCR4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e balixafortide (POL 6326)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 09/01/2024","start_date":" 09/01/2024","primary_txt":" Primary completion: 08/25/2025","primary_completion_date":" 08/25/2025","study_txt":" Completion: 12/25/2025","study_completion_date":" 12/25/2025","last_update_posted":"2024-12-03"},{"id":"f6a843ff-b9a4-47ba-9949-917077f9fea2","acronym":"POLTER","url":"https://clinicaltrials.gov/study/NCT04826016","created_at":"2021-04-01T16:52:30.884Z","updated_at":"2024-07-02T16:35:53.007Z","phase":"Phase 1/2","brief_title":"POL6326 (Balixafortide) Plus Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast Cancer","source_id_and_acronym":"NCT04826016 - POLTER","lead_sponsor":"MedSIR","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • Halaven (eribulin mesylate) • balixafortide (POL 6326)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/16/2022","start_date":" 03/16/2022","primary_txt":" Primary completion: 03/16/2022","primary_completion_date":" 03/16/2022","study_txt":" Completion: 03/16/2022","study_completion_date":" 03/16/2022","last_update_posted":"2023-03-20"},{"id":"784befad-6ca4-4afd-82e0-e21a4760b690","acronym":"","url":"https://clinicaltrials.gov/study/NCT01837095","created_at":"2021-01-17T17:26:17.947Z","updated_at":"2024-07-02T16:37:06.883Z","phase":"Phase 1","brief_title":"Dose Escalation of POL6326 in Combination With Eribulin in Patients With Metastatic Breast Cancer","source_id_and_acronym":"NCT01837095","lead_sponsor":"Polyphor Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Halaven (eribulin mesylate) • balixafortide (POL 6326)"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 06/01/2013","start_date":" 06/01/2013","primary_txt":" Primary completion: 08/01/2018","primary_completion_date":" 08/01/2018","study_txt":" Completion: 08/01/2018","study_completion_date":" 08/01/2018","last_update_posted":"2018-09-14"}]